IBRX ImmunityBio, Inc.
Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR ImmunityBio, Inc. (IBRX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: FDA approval of ANKTIVA in April 2024; commercial sales commenced but revenue timing and sufficiency remain uncertain
- • Material update: Revenue Interest Payment Agreement (RIPA) restricts operations, affects cash flow, and may impede capital raising flexibility
Quarterly Financial SummaryXBRL
Revenue
$32M
▲ +425.1% YoY▲ +21.3% QoQ
Net Income
-$67M
▲ +21.6% YoY▲ +27.3% QoQ
Operating Margin
-173.5%
▲ +114082bp YoY▲ +9625bp QoQ
Net Margin
-209.8%
▲ +119425bp YoY▲ +14049bp QoQ
ROE
12.8%
Total Assets
$519M
EPS (Diluted)
$-0.06
▲ +53.8% YoY▲ +45.5% QoQ
Operating Cash Flow
-$69M
▲ +30.2% YoY▲ +13.6% QoQ
Source: XBRL data from ImmunityBio, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ImmunityBio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.